Please assess the completion status of the following clinical trial:

Trial Title: Infinnium-Core™ Registry for the Treatment of Patients With De Novo Coronary Lesions

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years.~2. Eligible for percutaneous coronary intervention (PCI).~3. Acceptable candidate for CABG.~4. Clinical evidence of ischemic heart disease and/or a positive territorial functional study. Documented stable angina pectoris ((Canadian Cardiovascular Society (CCS) Classification 1,2,3 or 4) or unstable angina pectoris with documented ischemia (Braunwald Class IB-C, IIB-C or IIIB-C), or documented silent ischemia.~5. The target lesion is a single de novo coronary artery lesion with ≥ 50% and \< 100% stenosis in one of the major epicardial territories (LAD, LCX or RCA). A second target lesion in another major epicardial vessel could be treated and this second lesion should fit with the inclusion/exclusion criteria and will receive the same type of stent.~6. The target lesion must be covered by one study stent, preferably with a margin of 3 mm on each side of the lesion.~7. The target lesion must be ≤ 37 mm in length by visual estimate.~8. The target reference vessel diameter must be ≥ 2.5 mm and ≤ 3.5 mm.~9. Patient or patient's legal representative has been informed of the nature of the study and agrees to its provisions and has provided written informed consent as notified / approved by the Institutional Review Board/Ethics Committee of the clinical site.~Exclusion Criteria:~1. Female of childbearing potential.~2. Documented left ventricular ejection fraction (LVEF) ≤ 25%.~3. Evidence of an acute Q-wave or non-Q-wave myocardial infarction within 72 hours preceding the index procedure.~4. Known allergies to the following: aspirin, clopidogrel bisulfate (Plavix®, Ceruvin) or ticlopidine (Ticlid®), heparin, paclitaxel, cobalt, chromium, contrast agent (that cannot be adequately pre-medicated).~5. A platelet count \<100,000 cells/mm3 or \> 700,000 cells/mm3 or a WBC \< 3,000 cells/mm3.~6. Acute or chronic renal dysfunction (creatinine \> 2.0 mg/dl or \> 150 µmol/L).~7. Target vessel has evidence of thrombus.~8. Target vessel is excessively tortuous which makes it unsuitable for proper stent delivery and deployment.~9. Previous bare metal stenting (less than 1 year) anywhere within the target vessel.~10. Previous drug-eluting stenting anywhere within any epicardial vessel~11. The target lesion requires treatment with a device other than PTCA prior to stent placement (e.g., but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, etc.)~12. Significant (\> 50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run-off.~13. Heavily calcified lesion and/or calcified lesion which cannot be successfully predilated.~14. Target lesion is located in or supplied by an arterial or venous bypass graft.~15. Ostial target lesion.~16. Patient is currently participating in an investigational drug or device study, including its follow-up period.~17. Within 30 days prior to procedure, patient has undergone a previous coronary interventional procedure of any kind.~18. Within 60 days post-procedure, patient requires planned interventional treatment of any non-target vessel. Planned intervention of the target vessel after the index procedure is not allowed.~19. CVA within previous 6 months.~20. Unprotected Left Main (LM) coronary artery disease (stenosis \> 50%).~21. In the investigator's opinion, patient has a co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.~22. Planned surgery within 6 months after the index procedure.~23. Life expectancy less than 1 year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Infinnium-Core™ Paclitaxel eluting Coronary Stent (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility